PortfoliosLab logoPortfoliosLab logo
CNCR vs. CANC
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

CNCR vs. CANC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and Tema Oncology ETF (CANC). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period


CNCR

1D
0.00%
1M
0.00%
YTD
6M
1Y
3Y*
5Y*
10Y*

CANC

1D
-2.40%
1M
-2.10%
YTD
4.74%
6M
5.93%
1Y
49.25%
3Y*
107.71%
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

CNCR vs. CANC - Yearly Performance Comparison


CNCR vs. CANC - Sectors Allocation Comparison


Sectors
CNCR
CANC

Healthcare

96.6%
100.0%

Financial Services

3.3%

-

Basic Materials

-

-

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Energy

-

-

Industrials

-

-

Real Estate

-

-

Technology

-

-

Utilities

-

-

Healthcare

CNCR
96.6%
CANC
100.0%

Financial Services

CNCR
3.3%
CANC

-

Basic Materials

CNCR

-

CANC

-

Communication Services

CNCR

-

CANC

-

Consumer Cyclical

CNCR

-

CANC

-

Consumer Defensive

CNCR

-

CANC

-

Energy

CNCR

-

CANC

-

Industrials

CNCR

-

CANC

-

Real Estate

CNCR

-

CANC

-

Technology

CNCR

-

CANC

-

Utilities

CNCR

-

CANC

-

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CNCR vs. CANC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CNCR

CANC
CANC Risk / Return Rank: 7070
Overall Rank
CANC Sharpe Ratio Rank: 6363
Sharpe Ratio Rank
CANC Sortino Ratio Rank: 6565
Sortino Ratio Rank
CANC Omega Ratio Rank: 5555
Omega Ratio Rank
CANC Calmar Ratio Rank: 9090
Calmar Ratio Rank
CANC Martin Ratio Rank: 7878
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. CANC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and Tema Oncology ETF (CANC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

CNCR vs. CANC - Sharpe Ratio Comparison


Loading charts...

Sharpe Ratios by Period


CNCRCANCDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

2.14

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.04

Drawdowns

CNCR vs. CANC - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum CANC drawdown of -97.53%. Use the drawdown chart below to compare losses from any high point for CNCR and CANC.


Loading charts...

Drawdown Indicators


CNCRCANCDifference

Max Drawdown

Largest peak-to-trough decline

0.00%

-97.53%

+97.53%

Max Drawdown (1Y)

Largest decline over 1 year

-8.67%

Max Drawdown (3Y)

Largest decline over 3 years

-30.27%

Current Drawdown

Current decline from peak

0.00%

-56.58%

+56.58%

Average Drawdown

Average peak-to-trough decline

0.00%

-73.20%

+73.20%

Ulcer Index

Depth and duration of drawdowns from previous peaks

3.20%

Volatility

CNCR vs. CANC - Volatility Comparison


Loading charts...

Volatility by Period


CNCRCANCDifference

Volatility (1M)

Calculated over the trailing 1-month period

6.55%

Volatility (6M)

Calculated over the trailing 6-month period

16.79%

Volatility (1Y)

Calculated over the trailing 1-year period

0.00%

23.11%

-23.11%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

0.00%

280.39%

-280.39%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

0.00%

280.39%

-280.39%

CNCR vs. CANC - Expense Ratio Comparison

CNCR has a 0.79% expense ratio, which is higher than CANC's 0.75% expense ratio.


Dividends

CNCR vs. CANC - Dividend Comparison

CNCR has not paid dividends to shareholders, while CANC's dividend yield for the trailing twelve months is around 0.05%.


PositionTTM202520242023
CANC
Tema Oncology ETF
0.05%0.06%3.00%0.56%
CNCR
Loncar Cancer Immunotherapy ETF
0.00%0.00%0.00%0.00%

Frequently Asked Questions


On fees, CANC is cheaper at 0.75% per year. The better choice depends on whether you care most about return, fees, risk, or income.

CANC is cheaper with a 0.75% expense ratio, compared with 0.79% for CNCR.

CANC has the higher dividend yield at 0.05%, compared with 0.00% for CNCR.

They also come from different issuers: Exchange Traded Concepts and Tema. Their fees differ too: 0.79% for CNCR and 0.75% for CANC.

Portfolio Optimizer

Find the right allocation for CNCR and CANC

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer